Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.42 |
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166361 | 1.00 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL1222350 | 1.00 | TDP1 (0.49) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL570033 | 0.90 | MEN1 (0.50) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL7755318 | 0.88 | TDP1 (0.42) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL14721982 | 0.85 | TDP1 (0.50) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL16379307 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL13960156 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL2369074 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL5352030 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL12880606 | 0.85 | MEN1 (0.46) | TDP1MEN1GAAKMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388717-A1 | POLYUREA ACRYLATE OLIGOMER CONTAINING PROTECTED GROUPS AND PREPARATION METHOD AND APPLICATION THEREOF | UNIV ZHEJIANG (CN) | 2025-12-25 | — | — | US | claimed |
| CN-118359515-A | Betaine type zwitterionic lipid and preparation method thereof | 大连理工大学 | 2024-07-19 | — | — | CN | claimed |
| CN-114181200-B | Cationic liposome with efficient gene transfection efficiency and preparation and application thereof | 华中科技大学 | 2023-09-29 | — | — | CN | claimed |
| CN-110302390-B | Oxaliplatin precursor as phospholipid analogue, preparation method and application thereof | 中国科学院上海药物研究所 | 2021-08-06 | — | — | CN | claimed |
| CN-110845724-B | Polyamino acid, preparation method and application thereof | 中国科学院长春应用化学研究所 | 2021-01-08 | — | — | CN | claimed |
| CN-110845724-A | Polyamino acid, preparation method and application thereof | 中国科学院长春应用化学研究所 | 2020-02-28 | — | — | CN | claimed |
| CN-110302390-A | Class phosphatide oxaliplatin precursor, preparation method and the usage | 中国科学院上海药物研究所 | 2019-10-08 | — | — | CN | claimed |
| CN-105669682-B | A kind of intermediate of DPP-IV inhibitor | 成都先导药物开发股份有限公司 | 2019-08-30 | — | — | CN | claimed |
| CN-104448815-B | A kind of thermoplastic resin composition and preparation method thereof | 上海金发科技发展有限公司 | 2018-02-16 | — | — | CN | claimed |
| CN-105669682-A | Intermediates of DPP-IV inhibitor | 成都先导药物开发有限公司 | 2016-06-15 | — | — | CN | claimed |
| EP-4743440-A1 | IONIZABLE LIPIDS | eTheRNA immunotherapies NV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735440-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| WO-2026087635-A1 | DIHYDRO BENZOXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| WO-1994025477-A2 | NOVEL PEPTIDE NUCLEIC ACIDS | NIELSEN PETER E (DK) | 1994-11-10 | — | — | WO | disclosed |
| EP-0586618-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES. | BUCHARDT OLE (DK) | 1994-03-16 | — | — | EP | disclosed |
| EP-0586474-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT, Ole (DK) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020702-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020703-A1 | THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | TDP1 2524/4885MEN1 4299/4885GAA 4667/4885 |
| US-20250388717-A1 | POLYUREA ACRYLATE OLIGOMER CONTAINING PROTECTED GROUPS AND PREPARATION METHOD AND APPLICATION THEREOF | DCTD, UMPS, IMPDH1 | TDP1 29/4885MEN1 3297/4885GAA 3631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.